HRMY is a relatively new company in the biotech space and has held up incredibly well since it's IPO in 2020, forming a nice 2 year base. Price is currently sat just under $54 above which are clear skies. The weekly chart shows an up/down ratio of over 2, suggesting significant institutional accumulation